Biju Parekkadan

4.9k citations
85 papers · 3.8k indexed · 2 hit papers · h-index 25

Biju Parekkadan

82 papers receiving 3.7k citations

Hit Papers

Mesenchymal Stem Cells as Therapeutics6072010202620152020200400600

Peers

Biju Parekkadan
Comparison fields: 5 of 121
  • Genetics 2.1k
  • Hepatology 568
  • Surgery 1.5k
  • Biomaterials 311
  • Cancer Research 340
Replace Hitoshi Okochi with:
Hitoshi Okochi Japan
B. Linju Yen Taiwan
Ayelet Dar Israel
Yong Chan Bae South Korea
Elke Eggenhofer Germany
Mark Blackstad United States
Gustavo Mostoslavsky United States
Laurence Lagneaux Belgium
Maria G. Roubelakis Greece
Alain Chapel France
Biju Parekkadan relative to Hitoshi Okochi Japan Hitoshi Okochi's profile →
Citations per field
00.5×1.5×1.9×
Hitoshi Okochi · 1×
Citations per year

Countries citing papers authored by Biju Parekkadan

Since Specialization
Citations

This map shows the geographic impact of Biju Parekkadan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Biju Parekkadan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Biju Parekkadan more than expected).

Fields of papers citing papers by Biju Parekkadan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Biju Parekkadan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Biju Parekkadan. The network helps show where Biju Parekkadan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Biju Parekkadan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Biju Parekkadan Line = papers co-authored together Biju Parekkadan links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 20244
4 20241
5 20232
6 20231
7 20232
8 20221
9 202212
10 202112
11 20192
12 20182
13 20183
14 2018132
15 201612
16 201451
17 201428
18 201412
19 2014101
20 2007432

About Biju Parekkadan

Biju Parekkadan is a scholar working on Genetics, Oncology and Immunology, having authored 85 papers that have together received 3.8k indexed citations. Recurring topics across this work include Mesenchymal stem cell research (33 papers), 3D Printing in Biomedical Research (17 papers), Tissue Engineering and Regenerative Medicine (16 papers), CAR-T cell therapy research (11 papers), Cancer Cells and Metastasis (9 papers), CRISPR and Genetic Engineering (9 papers), Virus-based gene therapy research (8 papers) and Viral Infectious Diseases and Gene Expression in Insects (7 papers). The work is most often cited by research in Genetics (2.1k citations), Hepatology (568 citations) and Surgery (1.5k citations). Biju Parekkadan has collaborated with scholars based in United States, Netherlands and Japan. Frequent co-authors include Martin L. Yarmush, Jack M. Milwid, Arno W. Tilles, Daan van Poll, François Berthiaume, Naoya Kobayashi, Hiroshi Yagi, Alejandro Soto–Gutiérrez, Ronald G. Tompkins and Yuko Kitagawa. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026